Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Slides:



Advertisements
Similar presentations
Stop TB Strategy Planning Frameworks Mukund Uplekar TB Strategy, Operations and Health Systems, Stop TB Department, WHO.
Advertisements

February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
Consultative expert working group - proposals Barcelona
THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.
UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ROMANIAN DEVELOPMENT CAMP Second.
The Global Laboratory Initiative Assisting countries to implement the WHA resolution on MDR-TB Karin Weyer, WHO-STB, GLI secretariat John Ridderhof, CDC,
Sabelo Mbokazi Senior Policy Officer HIV/AIDS, TB, Malaria & OID
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
Pre Tender Meeting UNICEF Supply Division, December 2008 Rob Matthews UNICEF Vaccine Procurement for Developing Countries.
Technical Advisory Group meeting, WHO/WPRO
The Work of WHO in the South-East Asia Region The Work of WHO in the South-East Asia Region Biennial Report of the Regional Director 1 January
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
Regional Integration in the Context of HIV and AIDS, TB and Malaria: The case of SADC Presentation at the XIX International AIDS Conference, Washington.
UN Prequalification: UNICEF Perspective 5 th UN Prequalification stakeholders meeting 11th February 2009.
Global Health Program Guiding Principles April 2002.
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
1 |1 | Prequalification Programme – Stakeholders Meeting Geneva, February 2010 Access to Assured-Quality Praziquantel for the Control of Human Schistosomiasis.
 Critical Enablers for HIV, TB & Malaria Responses UNDP & Global Fund informal session 30 th meeting of the Global Fund Board Dr Mandeep Dhaliwal United.
The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.
Total health ODA commitments, US$ Billions.
UNITAID’s Market Approach in HIV Diagnostics Brenda Waning International AIDS Society 18 July, 2011 Rome.
UNITAID The HIV/AIDS Medicines Patent Pool Initiative October 2010.
Using the levy in order to finance recurring expenditures : the case of the International Drug Purchase Facility-UNITAID Meeting of experts on the solidarity.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Public-Private Partnerships -Selected Experiences in the Western Pacific & Cambodia- National Forum on Public-Private Partnership in Health 7 November,
Access to Medicines- OHCHR Geneva, October 11, 2010 Access to Medicines- the Global Fund Experience Pharmaceutical Management Unit October 11, 2010.
The Medicines Patent Pool Ellen ‘t Hoen UNITAID Consultative Forum Geneva, 4-5 October 2011.
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
UNITAID Matching Innovation and Sustainability: An Innovative Mechanism for Scaling-up Treatment for HIV/AIDS, TB and Malaria Jorge Bermudez, Executive.
Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
UNITAID The Role of UNITAID in Redressing the Shortage of TB medicines in International Procurement Improving the Quality of Essential Antituberculotic.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Working Draft - Last Modified :21:46 Printed UNITAID action plan - pediatric TB 0 “Securing timely access to quality, affordable TB drugs”
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
Pediatric TB Drugs Panel
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Achievements and impacts of WHO prequalification to date MSF perspective Carine Werder MSF international pharmacist coordinator Geneva, 11 th February.
Page 0 UNITAID’s Strategic Approach to HIV Diagnostics  Washington DC 22 July, 2012 XIX International AIDS Conference Brenda Waning.
The WHO Prequalification of Medicines Program - Introduction Tony Gould Manager, Prequalification of Medicines Program WHO.
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
Rethinking Health Innovation from the South WORKSHOP South Africa/ Cape town December 13 – 15 /2010.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
THE GLOBAL FUND SUSTAINING THE GAINS AND IMPACT Uganda November 2013.
Affordable healthcare Product Selection for TB, Malaria and HIV/AIDS Key issues for procurement IDA HIV/AIDS Group, Nienke Gruppelaar.
GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.
IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.
UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.
WHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections Common structure Universal Health Coverage SDGs Cascade.
VOLUNTARY PATENT POOLING FOR PUBLIC HEALTH A Model For Innovation And Access.
World Health Organization
Outline The Global Fund Strategy emphasizes the Key Populations
Taxonomy of Strategies
UNITAID Overview Joint Consultation on Seasonal Malaria Chemoprevention Ouagadougou, Burkina Faso, February 2017.
Global Drug Facility An innovative approach to supplying anti-TB drugs
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
Overview of vaccines prequalification
Raffaella Ravinetto, Chair
Access to HIV/AIDS Medicines The 3x5 strategy
WHO Global HIV/AIDS Staff Meeting
Prequalification Programme of Medicines (PQP): Introductory messages
Every Mother, Every Child: Closing the Gaps in HIV Management
Presentation transcript:

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines

Today 9.5 million people in need of treatment 4 million people on HIV/AIDS treatment and rapid expansion of access required Only 42% of needs currently being met of which 276,000 children (38% coverage) New treatment guidelines (CD4 <350) = more people in treatment Financial crisis: funding is not increasing Key challenge: keep HIV/AIDS on top of the global agenda Addressing Global HIV/AIDS Challanges

Today UNITAID Strategy: Portfolio

Scope of work in the Pharmaceutical value chain

Lower prices of treatments Enable more patients to be treated (e.g. with the same budget) Facilitate government adoption of improved medicines Formulation-related benefits FDCs: –Facilitate adherence, reduced risk of resistance, simplified supply chains Paediatric formulations: –Improved quality treatment for infants and children, reduced shipment costs for solids (vs. liquids) Heat-stable: –Enabled use in resource-poor settings Seeking efficient use of funds and public health benefits

Using innovative, global market based approaches to improve public health by increasing access to quality products to treat, diagnose and prevent HIV/AIDS, tuberculosis, malaria and related co- morbidities in developing countries. GoalObjectives To support adaptation of products targeting specific populations To assure availability in sufficient quantities and timely delivery to patients To ensure affordable and sustainably priced products To increase access to efficacious, safe and assured quality products that address Public Health problems Mission UNITAID’s mission is to contribute to scaling up access to treatment for HIV/AIDS, malaria and tuberculosis, primarily for people in low-income countries, by leveraging price reductions for quality diagnostics and medicines and accelerating the pace at which these are made available. [Constitution] UNITAID Strategy

Products to treat and diagnose HIV/AIDS, TB, and malaria Targeted prevention products that align with UNITAID goals and objectives Products for co-morbidities where: –burden of disease is high –efficacious and cost-effectiveness products are available –opportunity for positive public health & market impact is attainable Scope on Diseases and Products Strategy

Additional support and multi-year commitment to – Accelerate the pace at which priority HIV/AIDS, malaria and TB medicines are prequalified – Increase the number of QA laboratories in developing countries – Control the quality of strategic medicines close to treatment centers – : US$ 47 million approved Boosting WHO Quality Assurance Programmes

Support to WHO QA Diagnostic Programme –Prequalify priority HIV/AIDS and malaria diagnostics –Address costs concerns –Build or strengthen national regulatory capacity – support: US$ 7,5 million approved Boosting WHO Quality Assurance Programmes

 Diversifying supply sources to reduce prices  Expanding generic market size to reduce prices & expand access  Facilitating the development of improved formulations (e.g. Fixed Dose Combinations (FDCs), paediatric and heat-stable formulations)  Increasing legal certainty for generic companies and patent- holders  Reducing transaction costs for licensing agreements (e.g. FDCs) Patent Pool: innovation and better products

Reduced prequalification timeline for priority medicines: Quality assured atazanavir/r to achieve second line therapy objectives Quality assurance timing in line with the UNITAID project cycle Second Line ARV transition: Paediatric HIV/AIDS transition: ? Increased number of innovative FDCs, heat-stable and paediatric formulations facilitated by the Patent Pool Key role in providing technical support to manufacturers Address new products not based on innovators Quality APIs to boost global generic supply Strengthen capacity of NRAs Access to prequalified HIV and malaria diagnostics Partnership: Looking ahead

Today UNITAID Strategy: Portfolio